NDAORALTABLETPriority Review
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBRACA (rucaparib) is an oral small-molecule PARP inhibitor approved in December 2016 for treatment of ovarian cancer, particularly in patients with BRCA mutations or homologous recombination deficiency. It works by inhibiting poly(ADP-ribose) polymerase, leading to DNA damage accumulation and cell death in cancer cells. The drug represents an important precision medicine option in the poly(ADP-ribose) polymerase inhibitor class.
$43.0MPart D
Peak8.9 years to LOEProduct is at peak commercial stage with established market presence; team size likely stable with focus on market penetration and indication expansion rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Started Oct 2021
61 enrolled
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Started Nov 2020
20 enrolled
Leiomyosarcoma
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Started Apr 2020
13 enrolled
Metastatic Castration-resistant Prostate Cancer
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
Started Jan 2020
34 enrolled
Esophagus Cancer, AdenocarcinomaStomach Cancer, Adenocarcinoma
Rucaparib Maintenance Therapy in Advanced Cervical Cancer
Started Oct 2019
0Cervical Cancer
Worked on RUBRACA at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.